Precision Biopsy: Precision Biopsy submits IDE application to FDA to expand clinical trial of ClariCore Biopsy system

Precision Biopsy announced that it submitted an application to the U.S. Food and Drug Administration (FDA) for permission to enroll patients in the Transrectal Ultrasound (TRUS) and MR/Fusion arm of the company's study, expanding the scope of a clinical trial for its ClariCore Biopsy System in prostate cancer patients.